The answer, according to the analysis, is a carefully qualified yes. Researchers led by Iftikhar Khan and colleagues conducted a PRISMA-guided search of PubMed, Embase, and the Cochrane Library through May 2025, identifying randomized controlled trials that compared R² against rituximab monotherapy, chemoimmunotherapy, or lenalidomide alone. Four trials encompassing 1,315 patients made the final cut. The primary endpoints were the overall response rate, complete response, and partial response, while secondary outcomes included two-year progression-free survival, three-year overall survival, and adverse events. The results paint a picture of a regimen that is broadly equivalent to its competitors, but with important caveats that clinicians and patients alike will need to weigh.

On the headline efficacy measures, the two approaches were remarkably close. The relative risk for overall response with R² was 1.09, for complete response 1.06, and for partial response 1.19, none of which reached statistical significance. Three-year overall survival was essentially identical between the groups, with a relative risk of 1.00. In other words, patients receiving the doublet were just as likely to see their disease shrink and just as likely to be alive three years later as those on standard regimens. For a therapy that spares patients the toxicities of cytotoxic chemotherapy, that equivalence alone carries real clinical weight.

Progression-free survival, however, told a more complicated story. In the primary analysis, R² did not differ significantly from comparators at the two-year mark, with a relative risk of 1.53 and a confidence interval spanning 0.51 to 4.54, and a P value of 0.236. More troubling for the statistical integrity of that estimate was the heterogeneity statistic: an I² of 85.3 percent, indicating that the included trials varied so widely that pooling them produced an unstable result. High heterogeneity in a meta-analysis is a warning sign that the studies being combined may differ in populations, comparators, or design in ways that make a single summary estimate unreliable.

The researchers therefore ran a sensitivity analysis, excluding the largest trial, RELEVANCE, which contributed roughly half of the pooled population and was the only study comparing R² directly against chemoimmunotherapy. With RELEVANCE removed, a progression-free survival benefit for R² suddenly emerged, with a relative risk of 2.05, a confidence interval of 1.18 to 3.55, a P value of 0.038, and heterogeneity collapsing to zero. But this finding demands cautious interpretation. When a benefit appears only after deleting the biggest trial, the honest conclusion is that the evidence base is divided rather than decisive. The authors themselves conclude that R² represents a viable chemotherapy-free option rather than a demonstrably superior one, a distinction that matters enormously for treatment decisions.

Safety data from the analysis add further texture to the picture. Skin reactions were nearly three times more frequent with R², with a relative risk of 2.76 and a P value of 0.043, and diarrhea was roughly twice as common, with a relative risk of 1.98 and a P value of 0.004. These are the signature toxicities of lenalidomide, an oral agent that modulates the immune system through mechanisms that include altering cytokine production and stimulating T and natural killer cells. Encouragingly, severe hematologic toxicities, the dangerous drops in blood counts that drive many chemotherapy complications, were not significantly different between the groups, reinforcing the characterization of R² as having a manageable, predominantly non-hematologic toxicity profile.

The biological rationale behind the combination is what makes it scientifically compelling. Rituximab is a monoclonal antibody that binds CD20 on B cells, recruiting the immune system to destroy the cancer cells directly. Lenalidomide works differently, reshaping the tumor microenvironment and enhancing immune surveillance. Combining a targeted antibody with an immune-modulating small molecule is precisely the kind of rational pairing that has transformed treatment across hematology, and the follicular lymphoma data suggest the concept translates into real clinical activity without the collateral damage of cytotoxic drugs.

Yet the limitations of the evidence base are impossible to ignore. Four trials and 1,315 patients is a modest foundation for practice-changing conclusions, and the trials compared R² against three different kinds of comparators, from antibody monotherapy to full chemoimmunotherapy. That diversity is almost certainly the source of the extreme heterogeneity observed in the primary analysis. The authors call for longer-term randomized data with standardized comparators, and that request is well founded: without head-to-head trials using consistent control arms and extended follow-up, the field cannot determine whether R² merely matches standard care or, in selected populations, exceeds it.

For patients, the practical takeaway is one of options rather than revolution. Follicular lymphoma’s relapsing course means that treatment choices are rarely one-shot decisions; patients typically cycle through multiple lines of therapy over years or decades. A regimen that delivers response rates and survival comparable to chemoimmunotherapy while avoiding chemotherapy’s cumulative toxicity offers a meaningful alternative, particularly for older patients, those with comorbidities, or anyone prioritizing quality of life during long periods of disease control. The increased risk of skin reactions and diarrhea is real but generally manageable with dose adjustments and supportive care.

The study, which received no external funding and declared no competing interests, arrives at a moment when chemotherapy-free approaches are reshaping lymphoma care more broadly. As immunotherapies and targeted agents multiply, the central question in indolent lymphomas is shifting from whether we can treat the disease to how we can treat it with the least harm. This meta-analysis does not crown R² as a new standard, but it firmly establishes the doublet as a legitimate contender, backed by randomized evidence, and sets a clear agenda for the trials that must now follow to resolve the survival question the current data leave open.

Subject of Research: Efficacy of rituximab plus lenalidomide combination therapy compared with standard regimens in follicular lymphoma

Article Title: Efficacy of rituximab plus lenalidomide regimens in follicular lymphoma: a meta-analysis of randomized controlled trials

Article References: Khan, I., Habib, H., Butt, A. I., Hafeez, A. S., Mubarika, M., Alokozay, E., Shaharyar, M., Aleem, S., Alam, U., Shadab, H. A., Naeem, A. B., Nouman, M., Haris, H. M., Dogar, F. N., Fatima, Z. M., Azhar, M. J., Khan, S., Imtiaz, A., Malik, S. J., … Khan, A. (2026). Efficacy of rituximab plus lenalidomide regimens in follicular lymphoma: a meta-analysis of randomized controlled trials. Annals of Hematology. https://doi.org/10.1007/s00277-026-07248-x

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07248-x

Keywords: follicular lymphoma, rituximab, lenalidomide, meta-analysis, randomized controlled trials, chemoimmunotherapy, progression-free survival, non-Hodgkin lymphoma, immunomodulatory therapy, adverse events, hematology, cancer treatment